Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLT3-interleukin-2 chimeric antigen receptor gamma delta T cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**FLT3-interleukin-2 chimeric antigen receptor gamma delta T cells** are an investigational, engineered allogeneic-compatible gamma delta T-cell therapy for **acute myeloid leukemia**. The cells express an FLT3-directed chimeric antigen receptor to recognize and kill FLT3-expressing leukemic cells, together with interleukin-2 expression intended to support effector-cell viability, stem cell-like memory phenotypes, cytokine production, persistence, and repeated tumor-cell killing. In reported preclinical AML models, the IL-2-expressing FLT3 CAR-gamma delta T-cell construct showed greater antileukemic activity and durability than FLT3 CAR-gamma delta T cells without IL-2 expression.
- Other names
- FLT3-IL2-CAR-γδT cellsFLT3-IL2-CAR-gamma delta T cellsFLT-3-IL2-CAR-gamma delta T cellsFLT 3-IL2-CAR-gamma delta T cellsFLT3-interleukin-2 CAR-gamma delta T cellsFLT-3-interleukin-2 CAR-gamma delta T cellsFLT 3-interleukin-2 CAR-gamma delta T cells
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on FLT3-interleukin-2 chimeric antigen receptor gamma delta T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLT3-interleukin-2 chimeric antigen receptor gamma delta T cells.